Surgical management of hypertrophic cardiomyopathy in 2007: What is new?

Morgan L. Brown, Hartzell V Schaff

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy (HCM) has a variable clinical presentation and penetrance. Many patients will have a benign course, but others will become symptomatic and develop left ventricular outflow tract obstruction. Echocardiograph remains the standard for diagnosis and assessment of obstruction, but gains are being made in the our understanding of the genetic basis of this condition. Pharmacologic therapy remains the first-line therapy in the majority of patients, but alcohol septal ablation and surgical septal myectomy may be considered in many patients. Patients should assess both the benefits and risks of each procedure based on the best available current evidence. This paper summarizes important recent developments in HCM diagnosis and therapy.

Original languageEnglish (US)
Pages (from-to)350-354
Number of pages5
JournalWorld Journal of Surgery
Volume32
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Hypertrophic Cardiomyopathy
Ventricular Outflow Obstruction
Penetrance
Therapeutics
Alcohols

ASJC Scopus subject areas

  • Surgery

Cite this

Surgical management of hypertrophic cardiomyopathy in 2007 : What is new? / Brown, Morgan L.; Schaff, Hartzell V.

In: World Journal of Surgery, Vol. 32, No. 3, 03.2008, p. 350-354.

Research output: Contribution to journalArticle

@article{dc3d14ec11d44876bcbcb01c6efacb53,
title = "Surgical management of hypertrophic cardiomyopathy in 2007: What is new?",
abstract = "Hypertrophic cardiomyopathy (HCM) has a variable clinical presentation and penetrance. Many patients will have a benign course, but others will become symptomatic and develop left ventricular outflow tract obstruction. Echocardiograph remains the standard for diagnosis and assessment of obstruction, but gains are being made in the our understanding of the genetic basis of this condition. Pharmacologic therapy remains the first-line therapy in the majority of patients, but alcohol septal ablation and surgical septal myectomy may be considered in many patients. Patients should assess both the benefits and risks of each procedure based on the best available current evidence. This paper summarizes important recent developments in HCM diagnosis and therapy.",
author = "Brown, {Morgan L.} and Schaff, {Hartzell V}",
year = "2008",
month = "3",
doi = "10.1007/s00268-007-9412-9",
language = "English (US)",
volume = "32",
pages = "350--354",
journal = "Presentations from the 9th Annual Electric Utilities Environmental Conference",
issn = "0364-2313",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Surgical management of hypertrophic cardiomyopathy in 2007

T2 - What is new?

AU - Brown, Morgan L.

AU - Schaff, Hartzell V

PY - 2008/3

Y1 - 2008/3

N2 - Hypertrophic cardiomyopathy (HCM) has a variable clinical presentation and penetrance. Many patients will have a benign course, but others will become symptomatic and develop left ventricular outflow tract obstruction. Echocardiograph remains the standard for diagnosis and assessment of obstruction, but gains are being made in the our understanding of the genetic basis of this condition. Pharmacologic therapy remains the first-line therapy in the majority of patients, but alcohol septal ablation and surgical septal myectomy may be considered in many patients. Patients should assess both the benefits and risks of each procedure based on the best available current evidence. This paper summarizes important recent developments in HCM diagnosis and therapy.

AB - Hypertrophic cardiomyopathy (HCM) has a variable clinical presentation and penetrance. Many patients will have a benign course, but others will become symptomatic and develop left ventricular outflow tract obstruction. Echocardiograph remains the standard for diagnosis and assessment of obstruction, but gains are being made in the our understanding of the genetic basis of this condition. Pharmacologic therapy remains the first-line therapy in the majority of patients, but alcohol septal ablation and surgical septal myectomy may be considered in many patients. Patients should assess both the benefits and risks of each procedure based on the best available current evidence. This paper summarizes important recent developments in HCM diagnosis and therapy.

UR - http://www.scopus.com/inward/record.url?scp=39749084563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749084563&partnerID=8YFLogxK

U2 - 10.1007/s00268-007-9412-9

DO - 10.1007/s00268-007-9412-9

M3 - Article

C2 - 18202887

AN - SCOPUS:39749084563

VL - 32

SP - 350

EP - 354

JO - Presentations from the 9th Annual Electric Utilities Environmental Conference

JF - Presentations from the 9th Annual Electric Utilities Environmental Conference

SN - 0364-2313

IS - 3

ER -